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Synopsis Here we present a 1.47Å crystal structure of human inositol monophosphatase (IMPase) 
bound to the inhibitor ebselen (PDB entry 6ZK0). In the structure, ebselen forms a seleno-sulfide bond 
with cysteine 141 and ebselen-mediated contacts between two dimers give a ~222 tetramer. 
Abstract Inositol monophosphatase (IMPase) is inhibited by lithium, the most efficacious treatment 
for bipolar disorder. Several therapies have been approved, or are going through clinical trials, aimed 
at the replacement of lithium in the treatment of bipolar disorder. One candidate small molecule is 
ebselen, a selenium-containing antioxidant, which has been demonstrated to produce lithium-like 
effects, both in a murine model and in clinical trials.  
Here we present the crystallization and first structure of human IMPase covalently complexed with 
ebselen, a 1.47Å crystal structure (PDB entry 6ZK0). In the human-IMPase-complex ebselen, in a ring 
opened conformation, is covalently attached to Cys141, a residue located away from the active site.  
IMPase is a dimeric enzyme and, in the crystal structure, two adjacent dimers share four ebselen 
molecules, creating a tetramer with ~222 symmetry. In the crystal structure presented in this publication, 
the active site in the tetramer is still accessible, suggesting that ebselen may function as an allosteric 
inhibitor, or may block the binding of partner proteins. 
Keywords: Inositol monophosphatase; IMPase; Ebselen; Bipolar disorder; Tetramer. 
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1. Introduction  
Bipolar disorder is a chronic and debilitating psychiatric disorder, characterised by cycles of mania 
followed by severe depression, frequently accompanied by bouts of psychosis. Although antipsychotic 
agents are the preferred short-term method of treatment, more efficacious mood stabilising drugs, 
such as lithium, are used in long term clinical management (Geddes & Miklowitz, 2013). Lithium is 
the gold-standard treatment for bipolar, however, it has several serious side effects, such as nausea 
and cognitive impairment; in addition to a narrow therapeutic window (Rybakowski, 2016). Because 
of these liabilities, other, less efficacious mood stabilisers (e.g. Lamotrigine), are now often used in 
the treatment of bipolar disorder (Won & Kim, 2017). One enzyme inhibited by lithium, is inositol 
monophosphatase (IMPase) (Gill, et al. 2005), which has led to rational drug design targeting IMPase 
as a strategy for developing novel therapies for bipolar disorder (Brown & Tracy, 2013). 
IMPase is a key enzyme in the phosphatidylinositol intracellular (PI) signalling pathway, whereby 
IMPase dephosphorylates inositol 1-, 3-, or 4- phosphate, collectively known as InsP1, to produce 
myo-inositol, also known as free inositol (Atack et al., 1995). Cleavage of InsP1 into myo-inositol by 
IMPase is required for the recycling of inositol for subsequent use in the PI signalling pathway (Atack 
et al., 1995). Inositol is an essential precursor for the synthesis of PI, subsequently utilised in the 
synthesis of phosphatidylinositol phosphates (PIPs). These include PI(4,5)P2, which is cleaved by 
phospholipase C following GPCR signalling to release the second messengers diacylglycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3) (Phiel & Klein, 2001). The observed depletion of free inositol 
and accumulation of the substrate of IMPase, InsP1, coupled with a reduction in agonist-invoked IP3 
formation in cells and animals treated with lithium, led to the development of the inositol depletion 
hypothesis to explain the mechanism by which lithium exerts its effects (Berridge et al., 1989). 
The inositol depletion hypothesis, suggests that lithium produces a reduction in free inositol, primarily 
via blocking the recycling of inositol from InsP1, which leads to a decrease in PI(4,5)P2 and a slowing 
of the PIP signalling pathways that are postulated to be hyperactive in bipolar disorder (Harwood, 
2005). Further evidence to support the inositol depletion hypothesis come from observations that the 
mood stabilisers carbamazepine and valproic acid, also lead to depletions in free inositol and 
attenuation of PI(4,5)P2 signalling pathways (Williams et al., 2002). Therefore, targeting IMPase as a 
means of depleting free inositol has been of scientific interest, and has led to the search for new 
IMPase inhibitors.  
One such IMPase inhibitor is ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), an organoselenium 
compound, which functions as a glutathione peroxidase mimic (Nakamura et al., 2002). Ebselen is 
believed to act through reduction of reactive oxygen species (ROS), by binding covalently to cysteine 
residues or thiols to form seleno-sulfide bonds that lead to the pharmacological effect (Azad & 
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Tomar, 2014). However, it is not known whether the covalent binding of ebselen to specific groups is 
directly or indirectly responsible for its mechanism of action (Ulrich et al., 1996). 
Ebselen has been demonstrated to inhibit IMPase in a covalent manner, with effects consistent with 
that of lithium, through depletion of free inositol in mouse brain (Singh et al., 2013). Subsequent trials 
in a healthy cohort demonstrated that ebselen leads to decreased myo-inositol in the anterior cingulate 
cortex, in addition to effects consistent with attenuation of PIP signalling (Singh et al., 2015). At 
present ebselen is currently in stage 2 clinical trial for the treatment of bipolar disorder, however, 
results from the trial have not been released at the time of writing. 
Ebselen is known to bind to several proteins; crystal structures show ebselen covalently bound to 
cysteine residues of proteins including SOD1 (Capper., et al 2018; Chantadul et al 2020) and the 
transpeptidase LdtMt2 from Mycobacterium tuberculosis (De Munnik., et al 2019). Ebselen has also 
been reported to inhibit the Main protease from SARS-CoV-2 (Jin., et al 2020). These multiple targets 
suggest several potential therapeutic uses for ebselen, but also that there are likely to be off-target side 
effects. 
Whilst inhibition of IMPase by ebselen in-vitro has been demonstrated, confirmation of ebselen 
binding loci and the exact mechanism of action on IMPase remains unclear. Structures of IMPase 
have been published with a variety of ligands, including a structure of human IMPase with the lithium 
mimetic L-690,330 (Kraft et al., 2018). In this paper, we present a 1.47Å structure of ebselen 
covalently bound to cysteine residue 141 of human IMPase (PDB entry 6ZK0). This is the first 
structure of IMPase to be published demonstrating direct covalent binding of ebselen to IMPase.  
2. Materials and methods  
All reagents were purchased from Sigma-Aldrich or ThermoFisher unless otherwise stated.  
2.1. Macromolecule production 
The IMPase construct was described by Kraft et al. 2018, with Rossetta2 (DE3) E. coli used for 
IMPase production. A starter culture (10 ml) of transformed E. coli was grown overnight and used to 
inoculate 1L of LB medium containing 2.5 mM betaine, 660 mM sorbitol, 35 mg/ml chloramphenicol 
and 50 mg/ml ampicillin. The culture was grown at 37 ºC to an OD600 0.8. IMPase expression was 
induced by the addition of 0.5 mM IPTG, and the culture grown overnight at 25 ºC.  
E. coli cells were pelleted by centrifugation at 9,600g for 20 min at 4 ºC, and resuspended in 50 ml 
lysis buffer [20 mM Tris–HCl pH 7.8, 150 mM NaCl, 40 U/ml DNAse and one EDTA-free protease-
inhibitor tablet (Roche)]. The resuspended pellet was lysed by sonication, and the debris pelleted by 
centrifugation at 33,000g for 20 min at 4 ºC. The clarified sonicate was heat-treated at 68 ºC for 1 h 
and the precipitant pelleted by centrifugation at 32,000g for 20 min at 4 ºC. The supernatant was then 
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incubated at 4 ºC for 1 h with Co-NTA resin. After incubation, the resin was washed with seven resin 
volumes (RV) wash buffer [20 mM Tris–HCl pH 7.8, 150 mM NaCl, 15 mM imidazole] and IMPase 
eluted with 5 RV elution buffer [20 mM Tris–HCl pH 7.8, 150 mM NaCl, 250 mM imidazole].  
The eluted fractions were pooled and incubated overnight at 4 ºC with Pierce HRV 3C Protease 
solution. This removes the N-terminal tag (MHHHHHHLEVLFQ) by cleaving LEVLFQ↓GP 
(sequence in Table 1). Cleaved IMPase was purified initially by incubating with Glutathione 
Sepharose 4 Fast Flow Resin that had been pre-equilibrated with two column volumes of size-
exclusion chromatography (SEC) buffer (20 mM Tris–HCl pH 7.8, 150 mM NaCl). The flow through 
from the column was collected and concentrated to 5 ml and loaded onto a HiLoad 26/600 Superdex 
75 prep-grade SEC column pre-equilibrated with SEC buffer. Proteins were gel-filtered at a flow rate 
of 1 ml min-1 and the fractions containing IMPase were: pooled, buffer exchanged into storage buffer 
[20 mM Tris–HCl pH 7.8, 150 mM NaCl, 1 mM EDTA, 10%(v/v) glycerol] and concentrated to 20 
mg/ml using 10 kDa protein concentrators at 4,000g, prior to storage at -20 ºC. This protocol gave a 
typical yield of 2 mg IMPase per litre of culture.  
Table 1 Macromolecule production information  
Source organism  Human 
DNA source 
pET-15b vector containing human inositol 
monophosphatase with a N terminal His6 tag followed 
by an HRV 3C cleavage site. 
Cloning vector pET-15b 
Expression vector pET-15b 
Expression host E. coli BL21 Rosetta 2(DE3) 
Complete amino acid sequence of the construct 
produced 
MHHHHHHLEVLFQGPMADPWQECMDYAVTLARQAGEV 
VCEAIKNEMNVMLKSSPVDLVTATDQKVEKMLISSIK 
EKYPSHSFIGEESVAAGEKSILTDNPTWIIDPIDGTT 
NFVHRFPFVAVSIGFAVNKKIEFGVVYSCVEGKMYTA 
RKGKGAFCNGQKLQVSQQEDITKSLLVTELGSSRTPE 
TVRMVLSNMEKLFCIPVHGIRSVGTAAVNMCLVATGG  
ADAYYEMGIHCWDVAGAGIIVTEAGGVLMDVTGGPFD 
LMSRRVIAANNRILAERIAKEIQVIPLQRDDED 
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2.2. Crystallization  
Human IMPase crystallisation was carried out using Swissci 3 lens sitting drop plates, and the plates 
set up with a mosquito liquid handling robot (TTP Labtech). To co-crystallise IMPase with ebselen, a 
20 µl aliquot of IMPase, 20 mg/ml, in storage buffer [20 mM Tris–HCl pH 7.8, 150 mM NaCl, 1 mM 
EDTA, 10%(v/v) glycerol] was incubated with 50 mM ebselen (6 µl of 200 mM ebselen in DMSO). 
The sample was transferred to a 500 µl microcentrifuge tube and placed on a roller and incubated at 
room temperature for 30 min, prior to setting up crystallisation plates 
A reservoir solution comprising the following: 0.2 M MnSO4, 0.1 M MES, 28% PEG4000, pH 5.5, 
was added to the IMPase and ebselen solution at a 1:1 ratio and incubated at 20 ºC (see Table 2). 
Crystals appeared after 7 days and continued to grow until being harvested for data collection on day 
14; being cryoprotected by transfer into 20% (v/v) glycerol + reservoir solution (80% v/v) and flash 
cooled prior to data collection.   
Table 2 Crystallization conditions 
Method Sitting-drop vapour diffusion 
Plate type SWISSCI 3 lens crystallisation plate 
Temperature (K) 293 
Protein concentration 20 mg/ml 
Buffer composition of protein solution 
20 mM Tris–HCl pH 7.8, 150 mM NaCl, 1 mM EDTA, 
10% (v/v) glycerol 
Composition of reservoir solution 0.2 M MnS04, 0.1 M MES, 28% PEG4000, pH 5.5 
Volume and ratio of drop 100 nL, 1:1 
Volume of reservoir 50 µL 
 
2.3. Data collection and processing  
An X-ray diffraction dataset was collected from a single cryo-cooled crystal on beam-line I04-1 at the 
Diamond Light Source Synchrotron (Table 3). The data (2000, 0.1degree images) were processed 
with the Xia2 pipeline at Diamond (Winter, 2010) to give a 1.47 Å dataset in P 3121 with cell 
dimensions a=b=84.02 Å, c=150.22 Å, α=β=90°, γ=120°.  
There are nine crystal structures of human IMPase in the PDB with similar cell dimensions, all in 
space-group P3221; thus, the data were reindexed and remerged in P3221. The data were merged with 
version 0.7.4 of the program AIMLESS (Evans & Murshudov, 2013). The Rcp statistic, used to 
estimate cumulative radiation damage in AIMLESS (Diederichs, 2005), did not increase significantly 
over the 2000 frames. 
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Table 3 Data collection and processing  
Values for the outer shell are given in parentheses.  
Diffraction source I04-1 – Diamond Light Source 
Wavelength (Å) 0.91188 
Temperature (K) 100 
Detector Dectris Pilatus 6M-F 
Crystal-detector distance (mm) 260.0 
Rotation range per image (°) 0.1 
Total rotation range (°) 200 
Exposure time per image (s) 0.1 
Space group P3221 
a, b, c (Å)  84.02  84.02  150.22 
α, β, γ (°)  90.0  90.0 120.0 
Mosaicity (°)  0.080 
Resolution range (Å) 45.0-1.47 (1.50-1.47) 
Total No. of reflections 1155862 (53779) 
No. of unique reflections 104886 (5118) 
Completeness (%) 100.0 (100.0) 
Multiplicity 11.0 (10.5) 
〈 I/σ(I)〉  20.4 (1.2) 
CC1/2 1.0 (0.498) 
Rmeas 0.056 (2.123) 
Rpim 0.017 (0.652) 
Overall B factor from Wilson plot 
(Å2)  
22.2 
Test datasets were also produced, merging the first 800 and last 800 images from the dataset - to check for 
radiation damage effects (see below in refinement - section 2.4 - for details). The analysis suggested that the 
best dataset was obtained from using all data, and that although some radiation damage appeared to be present in 
the data, this damage was not reduced by removing the later frames from the dataset. 
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2.4. Structure solution and refinement  
The structure was solved by rigid body refinement from the 1.7 Å crystal structure of IMPase with 
Mn (PDB entry 6GJ0; Kraft et al., 2018).  Initial structure solution used the DIMPLE pipeline; this 
pipeline provides the user with a quick method to identify datasets that have a bound ligand or drug 
candidate in their crystal (http://ccp4.github.io/dimple/; Wojdyr et al., 2013).  
Initial maps showed clear electron density (Figure 1) for a single ebselen molecule attached to Cys141 
in both subunits A and B of the dimer (the P3221 cell has one dimer in the asymmetric unit). The 
ebselen was built onto Cys141A and Cys141B in coot (Emsley et al., 2010; Emsley, 2017). Restraints 
for the covalently bound ebselen were generated in AceDRG (Long et al., 2017) and the structure was 
refined using Refmac5 (Murshudov et al., 2011).  
Table 4 Structure solution and refinement  
Values for the outer shell are given in parentheses.  
Resolution range (Å) 24.44-1.47 (1.50-1.47) 
Completeness (%) 100.0 (100.0) 
σ cutoff   NA 
No. of reflections, working 
set 
99740 
No. of reflections, test set 5081 
Final Rcryst  0.1734 
Final Rfree  0.2011 
Cruickshank DPI 0.0662 
No. of non-H atoms   
Protein 3694 
Ebselen* 49 
Ligand  54 
Water 416 
R.m.s. deviations    
Bonds (Å) 0.014 
Angles (°) 1.856 
Average B factors (Å2)  29.4 
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Protein 27.9 
Ebselen 31.7 
Ligand  45.7 
Water 40.3 
Ramachandran plot    
Favoured regions (%) 98 
 Additionally allowed (%) 1.5 
Outliers(%)** 0.5 
* Ebselen - attached to Cys141A had only one atom with two positions (the selenium atom). Ebselen attached to 
Cys141B had every atom in two positions. There are sixteen non-hydrogen atoms in ebselen. 
** Lys36 is the only residue (just) outside allowed region in both subunits (phi/psi -100°/-110°)   
Although the electron density was very clear for the terminal phenyl ring of the compound (Figure 1c 
and 1d) and electron density maps have a large peak for the selenium (covalently bonded to the sulfur 
of Cys141), the electron density suggests some radiation damage has occurred to the sulfur-selenium 
bond (Weik et al., 2002; Garman, 2010). The data are consistent with a model in which some initial 
radiation damage occurred to the sulfur-selenium (within the first few degrees), after which a steady 
state occurred (bond reforming after breaking due to radiation) (Gerstel et al., 2015). 
Each active site contains three Mn2+ ions in 6GJ0 (Kraft et al., 2018), while in 2BJI (Gill et al., 2005) 
each active site contains three Mg2+ ions. In our structure, site 2 (Gill et al., 2005) does not have 
enough electron density for a Mn2+ ion (Mn2+ ions have twenty-three electrons). We modelled a 
similarly coordinated sodium ion at this site, because we have no Mg2+ ions in our crystallisation 
experiment (the protein comes in 150mM NaCl and the crystallisation buffer contains 200mM 
MnSO4). However, we cannot rule out the possibility that this is a Mg2+ ion, rather than a Na+ ion 
(both Na+ and Mg2+ ions have ten electrons). This 'site 2' is the position where lithium is postulated to 
bind with tetrahedral coordination geometry (Gill et al., 2005). However, the coordination geometry 
in our structure is consistent with two Mn2+ ions and one Mg2+ ion each with 'standard' octahedral 
coordination geometry.  Most of the active site metal atoms are modelled in two positions and have 
temperature factors similar to those of surrounding residues (Masmaliyeva & Murshudov, 2019).  
In the deposited structure (PDB 6ZK0), the ebselens on Cys141 in subunits A and B each have an 
occupancy of 0.6, but the selenium atoms are modelled in two positions (supplementary Figure 1). In 
the crystal, the selenium-sulfur bond has been modelled with an occupancy of 0.4 or 0.35 (see 
supplementary Figure 1). A second selenium position, observed in electron density maps, is some 1.3 
Å further away from the sulfur of Cys141 and this second position is likely caused by radiation 
induced cleavage of the seleno-sulfide bond (Gerstel et al., 2015). 
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3. Results  
3.1. Human IMPase structure with ebselen on cysteine 141 
The 1.47 Å crystal structure of human IMPase with ebselen (PDB entry 6ZK0) was solved from a 
structure of human IMPase in the same unit cell and space-group (6GJ0 - Kraft et al., 2018). Electron 
density maps (Figure 1) clearly showed ebselen attached only to a single cysteine, Cys141. The 
binding of ebselen to the Cys141 residue in each monomer does not lead to noticeable changes in 
conformation in the active site that would prevent the catalytic activity of IMPase. Additionally, the 
binding of ebselen to Cys141 does not appear to prevent dimer formation, as evidenced by the dimers 
(and tetramers) present in this structure (6ZK0). However, whilst this structure clearly shows ebselen 
bound to Cys141 on each monomer of IMPase, our structure does not rule out the possibility that 
Cys218 could be modified in-vivo.  
 
Figure 1 View of ebselen attached to Cys141 (PDB entry 6ZK0). (a) Overview of two ebselen molecules 
attached to A and A' (symmetry related) subunits around crystallographic twofold axis. One subunit (A) has 
carbons in orange and the second (A') subunit has carbons slate-blue (nitrogens are blue, carbons red, seleniums 
orange and sulphurs yellow-orange). Carbons in one ebselen are yellow and are cyan in the second ebselen. 
Hydrogen bonds near ebselen are indicated by dotted lines. (b) chemical structures of ebselen and ring-open 
ebselen on Cys141(drawn with Marvin, https://www.chemaxon.com). (c)  Final ebselen omit map (Fo-Fc) (3 
sigma green, 15 sigma blue). Note peaks on seleniums (blue mesh) are 20.5 and 19.6 sigma in this ebselen omit 
map. (d Original DIMPLE (Wojdyr et al., 2013) 2Fo-Fc map (1sigma – light blue), and difference map Fo-Fc (3 
sigma - orange). For subunit A the DIMPLE refined structure with waters (small red spheres) refined into the 
density for the ebselen is shown. For the A' subunit the 'final' coordinates (including ebselen) are shown. 
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IMPase contains seven cysteine residues, amino acids 8, 24, 125, 141, 184, 201 and 218, of these 
residues, only Cys218 is near the active site. Four of the cysteine residues are buried and would not be 
expected to be accessible to modification by ebselen (cysteines 8, 125, 201 and 218). Of the three 
cysteines that have some surface accessibility in the monomer, one of them, Cys184 is largely buried 
in the dimer interface as shown in Figure 2 (PDB entry 6ZK0). The procedure used to co-crystallise 
ebselen with IMPase allowed partial oxidation to form the Cys141 - ebselen seleno-sulfide bond (Fig 
1.). In our structure Cys24 has some surface accessibility when reduced, but when oxidised forms a 
disulphide with Cys125 (Figure 2). Cys125 has no surface accessibility whether oxidised or reduced. 
A partial Cys25-Cys125 disulphide is also observed in 6GJ0 (Kraft et al., 2018). 
 
Figure 2 Cysteine residues in IMPase with ebselen bound to Cys141 (PDB entry 6ZK0). IMPase is shown as 
with a Ca ribbon trace and the side-chains of the seven cysteines are shown in stick on the ‘red’ subunit. The 
second subunit in the dimer is shown in cyan. A semi-transparent surface is shown; note that where the sulphurs 
of the cysteine residues are on the surface of the protein, the surface is yellow (Cys24 and Cys141). Cys184 also 
has some surface accessibility in the monomer, but is largely buried at the dimer interface, so no yellow is 
visible for Cys184 in this figure.  
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Previous research suggested that Cys218 is the primary reactive cysteine residue (Knowles et al., 
1992), supported by reduced inhibition of C218A IMPase by ebselen (Singh et al., 2013). In the 
structure reported here (PDB entry 6ZK0), and other human IMPase structures, Cys218 is largely 
buried, and therefore seems an unlikely target for modification, as it is unclear as to how ebselen 
would gain access. If the side-chain of Cys218 is modified by ebselen it would likely lead to 
substantial reorganisation of the protein structure; Asp220 coordinates an active site metal ion.  
From our structure, it appears that Cys141 is likely to be the primary binding site of ebselen. The 
sulfur group of this residue is exposed on the surface of IMPase (Figure 2), and this residue is not in 
close proximity to another cysteine residue, in either the monomeric or dimer form, so unlikely to 
form a disulphide bond (PDB entry 6ZK0). Cys141 is conserved in mammals (Knowles et al., 1992; 
Singh et al., 2013), and an analogous cysteine residue (Cys138) is present in Staphylococcus aureus 
IMPase. Given this level of conservation, it is probable that Cys141 is a functionally important 
residue in IMPase (Dutta et al., 2014). 
Cys141 has previously been shown to be a reactive cysteine residue, demonstrated through affinity for 
the thiol probes pyrene-maleimide (Greasley et al., 1994) and n-ethylmaleimide (Knowles et al., 
1992). In this structure, ebselen is in an open ring conformation with the selenium atom forming a 
seleno-sulfide bond with the sulfur group of Cys141, which is consistent with the known binding 
mechanism of ebselen (Capper et al., 2018). Each monomer of IMPase in this structure has a single 
ebselen molecule bound to Cys141 (PDB entry 6ZK0). 
Whilst Cys141 conservation would suggest a critical role of this residue, the exact function remains 
unclear. The residue is not in close proximity to the active site, therefore the residue is unlikely to be 
involved in catalytic activity. One possibility is that the residue may undergo post translational 
modification in-vivo, and may be redox active (Marino & Gladyshev, 2012), linking ebselen to 
therapeutic effects as a known antioxidant.  
3.2. Ebselen bound IMPase is observed to form a tetramer with 222 symmetry in the solid 
state. 
Figure 3 shows the position of Cys141 on the subunits A and B in an IMPase dimer. The two ebselen 
molecules covalently bound to each dimer and localise with two other ebselen molecules on a second 
dimer. The 2 ebselen molecules on each dimer increase contacts with a neighbouring dimer, which 
gives a tetramer with ~222 symmetry in the crystal. However, as shown in Figure 3 (panels g and h), 
the active site still appears accessible.  
Interestingly, other members of the IMPase superfamily, including Fructose-1,6-bisphosphate 
(FBPase), have been observed to have both dimer and tetramer forms (Hines et al., 2007). Tetrameric 
forms of IMPase have also been observed in the anaerobic hyperthermophilic eubacterium T. 
maritima (Stieglitz et al., 2007). 
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Figure 3 Orthogonal views of IMPase dimer (and tetramer) showing ebselen on Cys141 and metal ions in the 
active sites based on the structure of PDB entry 6ZK0. (a) The two subunits in the dimer are shown as green 
(subunit A) and cyan (subunit B) cartoons with ebselen attached to Cys141A and Cys141B in space-fill. Metal 
ions (Mn2+/Na+) at each active site are shown as grey spheres. (b) and (c) - orthogonal views. (d),(e),(f). Same 
views as (a),(b),(c) but also showing a second dimer related by a crystallographic twofold axis. Subunit A' is in 
yellow and B' in magenta. The view in (e) is along the crystallographic twofold that rotates the A-B dimer 
(green/cyan) onto the A'-B' dimer (yellow-magenta). (g), (h). Two views of the tetramer from 'underneath'. 
Showing that the three metal ions (grey/black spheres) at each active site are still accessible in the tetramer. In 
view (h), a surface is shown on both dimers. 
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4.  Discussion  
The IMPase crystal structure that is presented (PDB entry 6ZK0) has ebselen covalently attached to 
Cys141, however it is not clear to what extent this binding brings about ebselen’s inhibitory effects on 
IMPase. It is possible that the modification on Cys141 is biologically relevant, and that this is a 
cysteine residue that is modified in vivo by ebselen, with binding over the previously suggested 
preferred residue Cys218 (Singh et al., 2013). Cys141 has been shown to be a reactive cysteine 
residue (Greasley et al., 1994), so it possible that ebselen binding at Cys141 causes inhibition of 
IMPase. However, the binding of ebselen does not affect the conformation of the active site or prevent 
dimer formation; with the high conservation of Cys141 across species, it is likely to be a functional 
residue with a potential regulatory redox role.  
There is evidence that modulation of IMPase away from the active site and dimer interface can affect 
activity; synthetic peptides that disrupt IMPase-calbindin interactions prevent calbindin mediated 
activation of IMPase (Noble et al., 2018) and mediate antidepressant-like effects in mice (Levi et al. 
2013). It is possible that ebselen interferes with accessory protein binding, possibly by formation of 
the tetramer seen in the crystal, to moderate the activity of IMPase in-vivo.  
However, the possibility that the conditions used in crystallisation do not reflect physiological 
conditions and that, in vivo, Cys141 and Cys218 could be modified differently by ebselen, cannot be 
ruled out. The binding of ebselen to Cys141 does not appear to have significantly altered the structure 
of the dimer or the active site. Should the ebselen/IMPase tetramers observed prove to be biologically 
relevant, this suggests a new mechanism for the regulation and subsequent inhibition of IMPase that 
could be utilised in the development of novel therapeutics. 
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